(Total Views: 541)
Posted On: 11/01/2022 6:17:39 PM
Post# of 148870
I believe Dr. Arman is very calculating and intentional with every word he's putting out... and so if you listen carefully there is indeed much potent information said in less than eight minutes of his scripted presentation, including the following regarding the HIV MDR BLA:
Results from Leronlimab to teach the medical community and the world!
Here's another statement by Dr. Arman about Leronlimab having "generated Compelling clinical signals to date:"
Dr. Arman speaks of new members to the Board and continued corporate re-structuring as well as a focused development strategy to transform into a more effective and efficient biotechnology company to bring innovative therapy to difficult to treat diseases, such as NASH:
Another point he made is focusing on Colo-Rectal and Breast Cancer where they have Fast Track Designation for mTNBC:
Dr. Arman said the word "soon" as well as "providing an update" and "plan to follow up on" in the above comments so I can imagine information and findings newsworthy of PRs when these things happen... much to look forward to for me.
Quote:
By the time we publish those positive results in the Peer Reviewed Journal soon, which we believe will help others in the medical and clinical communities further understand the enormous potential of Leronlimab.
Results from Leronlimab to teach the medical community and the world!
Here's another statement by Dr. Arman about Leronlimab having "generated Compelling clinical signals to date:"
Quote:
NASH and Oncology and other HIV related indications. Where there remains substantial unmet clinical needs and where Leronlimab's generated Compelling clinical signals to date.... We remain committed to the continued development of Leronlimab in these indications and look forward to Re-Starting Trials soon.
Dr. Arman speaks of new members to the Board and continued corporate re-structuring as well as a focused development strategy to transform into a more effective and efficient biotechnology company to bring innovative therapy to difficult to treat diseases, such as NASH:
Quote:
The results from that trial allowed us to identify appropriate dosing strategy for our next NASH trial. And demonstrating potential anti-fibrotic activity is an exciting outcome that we plan to study in future trials with correlated liver biopsies in a larger sample of patients. We will be providing an update on our NASH clinical program in the next investor call.
Another point he made is focusing on Colo-Rectal and Breast Cancer where they have Fast Track Designation for mTNBC:
Quote:
Our Pooled Data in the Relapsed Refractory TNBC population showed promising survival data that we plan to follow up on.
Dr. Arman said the word "soon" as well as "providing an update" and "plan to follow up on" in the above comments so I can imagine information and findings newsworthy of PRs when these things happen... much to look forward to for me.
(11)
(0)Scroll down for more posts ▼
